Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in advanced hepatocellular carcinoma
NCT03163992Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Dec 2017
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Samsung Medical Center. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03163992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03163992.